Ch. 16 Drug Cards - Emotional, Mood, and Behavioral Disorders

Question 1

sertraline (Zoloft) Therapeutic Class:

Answer 1

Antidepressant

Question 2

sertraline (Zoloft) Pharmacologic Class

Answer 2

Selective serotonin reuptake inhibitor (SSRI)

Question 3

sertraline (Zoloft) is used for what?

Answer 3

treatment of depression, anxiety, obsessive-compulsive disorder, and panic.

Question 4

sertraline (Zoloft) MOA

Answer 4

inhibit the reuptake of serotonin in the brain.

Question 5

How would you administer sertraline as an oral liquid?

Answer 5

mix with water, ginger ale, lemon/lime soda, lemonade, or orange juice.

Question 6

When administering sertraline (Zoloft), when should the nurse take extreme precautions?

Answer 6

in patients with:
cardiac disease
hepatic impairment
seizure disorders
suicidal ideation
mania
hypomania.

Question 7

sertraline (Zoloft) interactions with MAOIs

Answer 7

may cause neuroleptic malignant syndrome, extreme hypertension, and serotonin syndrome

Question 8

confusion, anxiety, restlessness, hypertension, tremors, sweating, hyperpyrexia, or ataxia.

Answer 8

S&S of serotonin syndrome

Question 9

Patient education for sertraline (Zoloft) & MAOIs

Answer 9

Do not take concurrently w/ a MAOI or within 5 weeks of discontinuing MAOI meds

Question 10

imipramine (Tofranil) Therapeutic Class:

Answer 10

Antidepressant; treatment of nocturnal enuresis in children

Question 11

imipramine (Tofranil) Pharmacologic class

Answer 11

Tricyclic Antidepressant (TCA)

Question 12

Side effect of TCAs

Answer 12

paradoxical diaphoresis

Question 13

When a patient is prescribed imipramine (Tofranil), diaphoresis may not be a reliable indicator of what?

Answer 13

other disease states such as hypoglycemia.

Question 14

imipramine (Tofranil) causes what?

Answer 14

anticholinergic effects

Question 15

imipramine (Tofranil) MOA

Answer 15

blocks the reuptake of serotonin and norepinephrine

Question 16

Unlabeled uses of imipramine (Tofranil)

Answer 16

intractable pain
anxiety disorders
withdrawal syndromes from alcohol and cocaine

Question 17

Patient education for imipramine (Tofranil)

Answer 17

Therapeutic effectiveness may not occur for 2 or more weeks.

Question 18

Photosensitivity

Answer 18

Side effect of imipramine (Tofranil)

Question 19

imipramine (Tofranil) contraindications

Answer 19

Should not be used in cases of:
acute recovery after MI
defects in bundle-branch conduction
narrow-angle glaucoma
severe renal or hepatic impairment.

Patients should not use this drug within 14 days of discontinuing MAOIs.

Question 20

imipramine (Tofranil) drug interactions

Answer 20

many
CNS depressants - sedation
cimetidine (Tagamet) - increased serum levels and possible toxicity
clonidine - reverse antihypertensive effects and potentiate CNS depression
Oral contraceptives - increase or decrease imipramine levels
Disulfiram - delirium and tachycardia

Question 21

altered blood glucose tests.
Elevation of serum bilirubin and alkaline phosphatase is likely.

Answer 21

imipramine (Tofranil) lab tests

Question 22

phenelzine (Nardil) Therapeutic classification

Answer 22

antidepressants

Question 23

phenelzine (Nardil) Pharmacologic classification

Answer 23

MAOI

Question 24

Washout periods of 2 to 3 weeks are required before introducing other drugs.

Answer 24

phenelzine (Nardil) Administration alerts

Question 25

Abrupt discontinuation of phenelzine (Nardil) may cause what?

Answer 25

rebound hypertension.

Question 26

Patient education for the patient taking phenelzine (Nardil)

Answer 26

Drug effects may persist for 2 to 3 weeks after therapy is discontinued.

Question 27

Severe hypertension may occur when ingesting foods containing tyramine.

Answer 27

phenelzine (Nardil) adverse effects

Question 28

phenelzine (Nardil) contraindications

Answer 28

Patients with: cardiovascular or cerebrovascular disease hepatic or renal impairment

Question 29

phenelzine (Nardil) drug interactions

Answer 29

interacts with MANY drugs

Question 30

methylphenidate (Ritalin, Concerta) Therapeutic Classification:

Answer 30

Attention deficit–hyperactivity disorder (ADHD) drug

Question 31

methylphenidate (Ritalin, Concerta) Pharmacologic Classification

Answer 31

CNS stimulant

Question 32

methylphenidate (Ritalin, Concerta) Controlled Substance Schedule

Answer 32

Schedule II drug

Question 33

methylphenidate (Ritalin, Concerta) actions

Answer 33

heightened alertness with focus and attention

Question 34

Activation is partially achieved by the release of neurotransmitters such as norepinephrine and dopamine. Impulsiveness, hyperactivity, and disruptive behavior are usually reduced within a few weeks.

Answer 34

methylphenidate (Ritalin, Concerta) MOA

Question 35

methylphenidate (Ritalin, Concerta) adverse effects in a non-ADHD patient

Answer 35

nervousness and insomnia

Question 36

methylphenidate (Ritalin, Concerta) Black Box Warning

Answer 36

Scheule II drug with high abuse potential

Question 37

methylphenidate (Ritalin, Concerta) drug interactions

Answer 37

Interacts with many drugs